Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04069156 · ClinicalTrials.gov registry record · NA
The ARIES HeartMate 3 Pump IDE Study
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 628
- Enrollment target
NCT04069156 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 628 participants.
The verdict
NCT04069156, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 628 participants
- Enrollment target
Study Summary
Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo
Interventions
- DRUG Placebo oral tablet
- DEVICE LVAD Implant
- DRUG Aspirin 100mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 628 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2023-08-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04069156
The ClinicalTrials.gov registry entry for NCT04069156 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 628 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT04069156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04069156 about?
NCT04069156 is a clinical study titled "The ARIES HeartMate 3 Pump IDE Study". Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo
What is the current status of trial NCT04069156?
This trial is currently completed. It is a NA study. The enrollment target is 628 participants. The study started on 2020-07-14. Estimated completion is 2023-08-10.
What interventions are being tested in trial NCT04069156?
The interventions under investigation include: Placebo oral tablet (DRUG), LVAD Implant (DEVICE), Aspirin 100mg (DRUG).
Who is sponsoring clinical trial NCT04069156?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.